% | $
Quotes you view appear here for quick access.

Amarantus Bioscience Holdings, Inc Message Board

  • teamonfuego teamonfuego Dec 17, 2012 9:31 AM Flag

    It's all about the patents

    It's all about the MANF patents. These proteins can be modified to treat the diseases they are trying to treat (like Parkinsons, Myocardial Infarction, Alzheimers, TBI, etc) better but anyone that wants to work on MANF or anything similar to it has to go through AMBS. There's a reason why Hermo Pharma challenged these patents. Ask yourself why Hermo Pharma felt compelled to challenge their MANF patents. If you don't believe me then read this interview with the partner of Hermo Pharma, who is a VC backed biotech startup and received $700k in funding from the Michael J. Fox Foundation on why they challenged the patents:

    These are his own words:
    "Their patent covers all sequences with 90% homology to MANF (182 amino acid protein -- variation in 18 amino acid residues allowed, 20 options for each position -- you do the math; the result is an astronomical number of variants!). According to the patent law this causes "an undue burden" to anyone who would like to test these variants for activity. This is the explanation why we have challenged the EPO granted patent on MANF for Amarantus."

    Right now MANF is producing much better results than GDNF produced at this stage and GDNF was purchased for over $250 Million AT THIS STAGE of testing.

    AMBS is only worth $9 Million right now.

    Versus $250 Million.

    Do the math.

    And listen to people that know the science like Dr. Rubinfeld who said "I believe that MANF could be one of the biggest successes that I have ever seen". This isn't just some schlub. It's the co-founder of Amgen.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.39+0.04(+11.43%)Nov 30 3:59 PMEST